Case Study

Actionable results to inform your treatment decisions

PrismRA® identifies a patient’s likelihood of response to TNF inhibitor (TNFi) therapies. Even patients with similar clinical presentations can vary widely in their likelihood of inadequately responding to medications.

This below case study offers an example of two similar patients with rheumatoid arthritis (RA) whose providers administered the PrismRA test to help guide their treatment decisions.

Case Study

Two similar female patients with RA failed to control their symptoms with conventional DMARDs for 3 consecutive months. Both patients are now considering starting their first targeted therapy.

Case Study

Two similar female patients with RA failed to control their symptoms with conventional DMARDs for 3 consecutive months. Both patients are now considering starting their first targeted therapy.

Mary
Age: 57
Time Since Dx: 1 year
Sarah
Age: 57
Time Since Dx: 4 years
On Methotraxate
On Methotraxate
Yes
On Methotraxate
Yes
Anti-CCP
Anti-CCP
Negative
Anti-CCP
Negative
Rheumatoid factor
Rheumatoid factor
Negative
Rheumatoid factor
Positive
C-reactive protein
C-reactive protein
0.78
C-reactive protein
3.63
Swollen joint count
Swollen joint count
8
Swollen joint count
8
Tender joint count
Tender joint count
15
Tender joint count
12
Physician global
Physician global
50
Physician global
43

Patient's PrismRA results and proposed treatment decisions

PrismRA Results
PrismRA Results
12.2
PrismRA Results
5.4
Non-response signal
Non-response signal
High
Non-response signal
Not Detected
Likelihood of non-response
Likelihood of non-response
≥ 90%
Likelihood of non-response
N/A
Actual response to anti-TNF Therapy
Actual response to anti-TNF Therapy
Inadequate
Actual response to anti-TNF Therapy
Adequate
Proposed treatment decision
Proposed treatment decision
Alternative Therapy
Proposed treatment decision
Anti-TNF